🚀 VC round data is live in beta, check it out!
NeOnc Valuation Multiples
Discover revenue and EBITDA valuation multiples for NeOnc and similar public comparables like Cereno Scientific, Searle Co., Humacyte, Sensorion and more.
NeOnc Overview
About NeOnc
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).
Founded
2005
HQ
Employees
3
Website
Sectors
Financials (LTM)
EV
$218M
NeOnc Financials
NeOnc reported last 12-month revenue of —.
In the same LTM period, NeOnc generated had net loss of ($54M).
Revenue (LTM)
NeOnc P&L
In the most recent fiscal year, NeOnc reported revenue of $83K and EBITDA of ($9M).
NeOnc expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $83K | XXX | XXX | XXX |
| EBITDA | — | XXX | ($9M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (10958%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (8556%) | XXX | XXX | XXX |
| Net Profit | ($54M) | XXX | ($12M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (14336%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
NeOnc Stock Performance
NeOnc has current market cap of $214M, and enterprise value of $218M.
Market Cap Evolution
NeOnc's stock price is $9.43.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $218M | $214M | 0.0% | XXX | XXX | XXX | $-0.52 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNeOnc Valuation Multiples
NeOnc trades at 2621.1x EV/Revenue multiple, and (23.9x) EV/EBITDA.
NeOnc Financial Valuation Multiples
As of March 7, 2026, NeOnc has market cap of $214M and EV of $218M.
Equity research analysts estimate NeOnc's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
NeOnc has a P/E ratio of (4.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $214M | XXX | $214M | XXX | XXX | XXX |
| EV (current) | $218M | XXX | $218M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 2621.1x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (23.9x) | XXX | XXX | XXX |
| EV/EBIT | (4.2x) | XXX | (30.6x) | XXX | XXX | XXX |
| P/E | (4.0x) | XXX | (18.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (51.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified NeOnc Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
NeOnc Margins & Growth Rates
NeOnc's revenue in the last fiscal year declined by (100%).
NeOnc's revenue per employee in the last FY averaged $0.0M.
NeOnc Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (10958%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (25%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 4384% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 3669% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 8656% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
NeOnc Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Cereno Scientific | XXX | XXX | XXX | XXX | XXX | XXX |
| Searle Co. | XXX | XXX | XXX | XXX | XXX | XXX |
| Humacyte | XXX | XXX | XXX | XXX | XXX | XXX |
| Sensorion | XXX | XXX | XXX | XXX | XXX | XXX |
| Mycenax Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
NeOnc M&A Activity
NeOnc acquired XXX companies to date.
Last acquisition by NeOnc was on XXXXXXXX, XXXXX. NeOnc acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by NeOnc
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNeOnc Investment Activity
NeOnc invested in XXX companies to date.
NeOnc made its latest investment on XXXXXXXX, XXXXX. NeOnc invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by NeOnc
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout NeOnc
| When was NeOnc founded? | NeOnc was founded in 2005. |
| Where is NeOnc headquartered? | NeOnc is headquartered in United States. |
| How many employees does NeOnc have? | As of today, NeOnc has over 3 employees. |
| Who is the CEO of NeOnc? | NeOnc's CEO is Amir Heshmatpour. |
| Is NeOnc publicly listed? | Yes, NeOnc is a public company listed on Nasdaq. |
| What is the stock symbol of NeOnc? | NeOnc trades under NTHI ticker. |
| When did NeOnc go public? | NeOnc went public in 2025. |
| Who are competitors of NeOnc? | NeOnc main competitors are Cereno Scientific, Searle Co., Humacyte, Sensorion. |
| What is the current market cap of NeOnc? | NeOnc's current market cap is $214M. |
| What is the current revenue growth of NeOnc? | NeOnc revenue growth (vs. last FY) is (100%). |
| What is the current EV/Revenue multiple of NeOnc? | Current revenue multiple of NeOnc is 2621.1x. |
| Is NeOnc profitable? | No, NeOnc is not profitable. |
| What is the current net income of NeOnc? | NeOnc's last 12 months net income is ($54M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.